TY - JOUR
T1 - Clinician Attitudes and Beliefs Associated with More Aggressive Diagnostic Testing
AU - Korenstein, Deborah
AU - Scherer, Laura D.
AU - Foy, Andrew
AU - Pineles, Lisa
AU - Lydecker, Alison D.
AU - Owczarzak, Jill
AU - Magder, Larry
AU - Brown, Jessica P.
AU - Pfeiffer, Christopher D.
AU - Terndrup, Christopher
AU - Leykum, Luci
AU - Stevens, Deborah
AU - Feldstein, David A.
AU - Weisenberg, Scott A.
AU - Baghdadi, Jonathan D.
AU - Morgan, Daniel J.
N1 - Funding Information:
All statistical analyses were performed with Stata 15.1 (Stata Corp., College Station, Texas). Role of the funding source: this study was funded by a National Institutes of Health New Innovator award. The funder had no role in study design, completion, or analysis. Patients and the public were not involved in this research. Institutional review board approval was obtained at each of the 3 coordinating sites (Baltimore, Md; San Antonio, Texas; and Portland, Ore), for verbal informed consent with a waiver of documentation.
Funding Information:
Funding: This project was funded by National Institutes of Health National Library of Mediciine DP2LM012890 (New Innovator Award) to principal investigator DJM. The funder had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Funding Information:
Funding: This project was funded by National Institutes of Health National Library of Mediciine DP2LM012890 (New Innovator Award) to principal investigator DJM. The funder had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Conflicts of Interest: DK's work on this project was supported in part by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (P30 CA008748). CDF reports serving as the local site investigator for a Pfizer-sponsored Clostridioides difficile vaccine trial (protocol #B5091007) since July 2020 under a Cooperative Research and Development Agreement (CRADA) to VA Portland. DK discloses that her spouse serves on the scientific advisory board of Vedanta Biosciences and has equity interest, serves on the scientific advisory board of PFL-NYC, and provides consulting for Fimbrion. All other authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
Funding Information:
Conflicts of Interest: DK's work on this project was supported in part by a Cancer Center Support Grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center (P30 CA008748). CDF reports serving as the local site investigator for a Pfizer-sponsored Clostridioides difficile vaccine trial (protocol #B5091007) since July 2020 under a Cooperative Research and Development Agreement (CRADA) to VA Portland. DK discloses that her spouse serves on the scientific advisory board of Vedanta Biosciences and has equity interest, serves on the scientific advisory board of PFL-NYC, and provides consulting for Fimbrion. All other authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/7
Y1 - 2022/7
N2 - Background: Variation in clinicians’ diagnostic test utilization is incompletely explained by demographics and likely relates to cognitive characteristics. We explored clinician factors associated with diagnostic test utilization. Methods: We used a self-administered survey of attitudes, cognitive characteristics, and reported likelihood of test ordering in common scenarios; frequency of lipid and liver testing in patients on statin therapy. Participants were 552 primary care physicians, nurse practitioners, and physician assistants from practices in 8 US states across 3 regions, from June 1, 2018 to November 26, 2019. We measured Testing Likelihood Score: the mean of 4 responses to testing frequency and self-reported testing frequency in patients on statins. Results: Respondents were 52.4% residents, 36.6% attendings, and 11.0% nurse practitioners/physician assistants; most were white (53.6%) or Asian (25.5%). Median age was 32 years; 53.1% were female. Participants reported ordering tests for a median of 20% (stress tests) to 90% (mammograms) of patients; Testing Likelihood Scores varied widely (median 54%, interquartile range 43%-69%). Higher scores were associated with geography, training type, low numeracy, high malpractice fear, high medical maximizer score, high stress from uncertainty, high concern about bad outcomes, and low acknowledgment of medical uncertainty. More frequent testing of lipids and liver tests was associated with low numeracy, high medical maximizer score, high malpractice fear, and low acknowledgment of uncertainty. Conclusions: Clinician variation in testing was common, with more aggressive testing consistently associated with low numeracy, being a medical maximizer, and low acknowledgment of uncertainty. Efforts to reduce undue variations in testing should consider clinician cognitive drivers.
AB - Background: Variation in clinicians’ diagnostic test utilization is incompletely explained by demographics and likely relates to cognitive characteristics. We explored clinician factors associated with diagnostic test utilization. Methods: We used a self-administered survey of attitudes, cognitive characteristics, and reported likelihood of test ordering in common scenarios; frequency of lipid and liver testing in patients on statin therapy. Participants were 552 primary care physicians, nurse practitioners, and physician assistants from practices in 8 US states across 3 regions, from June 1, 2018 to November 26, 2019. We measured Testing Likelihood Score: the mean of 4 responses to testing frequency and self-reported testing frequency in patients on statins. Results: Respondents were 52.4% residents, 36.6% attendings, and 11.0% nurse practitioners/physician assistants; most were white (53.6%) or Asian (25.5%). Median age was 32 years; 53.1% were female. Participants reported ordering tests for a median of 20% (stress tests) to 90% (mammograms) of patients; Testing Likelihood Scores varied widely (median 54%, interquartile range 43%-69%). Higher scores were associated with geography, training type, low numeracy, high malpractice fear, high medical maximizer score, high stress from uncertainty, high concern about bad outcomes, and low acknowledgment of medical uncertainty. More frequent testing of lipids and liver tests was associated with low numeracy, high medical maximizer score, high malpractice fear, and low acknowledgment of uncertainty. Conclusions: Clinician variation in testing was common, with more aggressive testing consistently associated with low numeracy, being a medical maximizer, and low acknowledgment of uncertainty. Efforts to reduce undue variations in testing should consider clinician cognitive drivers.
KW - Clinician characteristics
KW - Medical overuse
KW - Utilization
UR - http://www.scopus.com/inward/record.url?scp=85128414184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128414184&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2022.02.036
DO - 10.1016/j.amjmed.2022.02.036
M3 - Article
C2 - 35307357
AN - SCOPUS:85128414184
SN - 0002-9343
VL - 135
SP - e182-e193
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 7
ER -